



Get Clarity On Generics

Cost-Effective CT & MRI Contrast Agents



**FRESENIUS
KABI**

WATCH VIDEO

AJNR

MRI Detection of Carotid Intraplaque Hemorrhage and Postintervention Cognition

S. Culleton, H. Baradaran, S.-E. Kim, G. Stoddard, J. Roberts, G. Treiman, D. Parker, K. Duff and J.S. McNally

AJNR Am J Neuroradiol published online 10 November 2022

<http://www.ajnr.org/content/early/2022/11/10/ajnr.A7701>

This information is current as of August 12, 2025.

MRI Detection of Carotid Intraplaque Hemorrhage and Postintervention Cognition

 S. Culleton,  H. Baradaran,  S.-E. Kim,  G. Stoddard,  J. Roberts,  G. Treiman,  D. Parker,  K. Duff, and  J.S. McNally



ABSTRACT

BACKGROUND AND PURPOSE: Cognitive improvement has been reported after carotid revascularization and attributed to treating stenosis and correcting hypoperfusion. This study investigated the effect of carotid intraplaque hemorrhage on postintervention cognition.

MATERIALS AND METHODS: In this institutional review board–approved single-center study, consecutive patients scheduled for carotid surgery were recruited for preoperative carotid MR imaging (MPRAGE) and pre- and postintervention cognitive testing using the Repeatable Battery for the Assessment of Neuropsychological Status. Pre- and postintervention scores were compared using *t* tests and multivariable linear regression.

RESULTS: Twenty-three participants were included, with endarterectomy performed in 20 (87%) and angioplasty/stent placement, in 3 (13%). Overall, statistically significant improvements occurred in the pre- versus postintervention mean Total Scale score (92.1 [SD, 15.5] versus 96.1 [SD, 15.8], *P* = .04), immediate memory index (89.4 [SD, 18.2] versus 97.7 [SD, 14.9], *P* < .001), and verbal index (96.1 [SD, 14.1] versus 103.0 [SD, 12.0], *P* = .002). Intraplaque hemorrhage (+) participants (*n* = 11) had no significant improvement in any category, and the attention index significantly decreased (99.4 [SD, 18.0] versus 93.5 [SD, 19.4], *P* = .045). Intraplaque hemorrhage (−) participants (*n* = 12) significantly improved in the Total Scale score (86.4 [SD, 11.8] versus 95.5 [SD, 12.4], *P* = .004), immediate memory index (82.3 [SD, 14.6] versus 96.2 [SD, 14.1], *P* = .002), delayed memory index (94.3 [SD, 14.9] versus 102.4 [SD, 8.0], *P* = .03), and verbal index (94.3 [SD, 13.2] versus 101.5 [SD, 10.7], *P* = .009). Postintervention minus preintervention scores for intraplaque hemorrhage (+) versus (−) groups showed statistically significant differences in the Total Scale score (−0.4 [SD, 6.8] versus 8.0 [SD, 8.5], *P* = .02), attention index (−5.9 [SD, 8.5] versus 4.3 [SD, 11.9], *P* = .03), and immediate memory index (4.2 [SD, 6.7] versus 12.2 [SD, 10.2], *P* = .04).

CONCLUSIONS: Cognitive improvement was observed after carotid intervention, and this was attributable to intraplaque hemorrhage (−) plaque. MR imaging detection of intraplaque hemorrhage status may be an important determinant of cognitive change after intervention.

ABBREVIATIONS: ACA = anterior cerebral artery; BMI = body mass index; IPH = intraplaque hemorrhage; PCA = posterior cerebral artery; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status

An association between dementia, carotid stenosis, and cognitive improvement following the restoration of blood flow was


Received May 11, 2022; accepted after revision October 1.

From the Department of Radiology (S.C., H.B., S.-E.K., J.R., D.P., J.S.M.), Utah Center for Advanced Imaging Research, Division of Epidemiology (G.S.), Department of Internal Medicine, Department of Surgery (G.T.), and Center for Alzheimer's Care, Imaging and Research (K.D.), University of Utah, Salt Lake City, Utah.

This work was supported by the American Heart Association Scientist Development Grant 17SDG33460420 (J.S. McNally) and the National Institutes of Health R01 HL127582 (J.S. McNally).

Please address correspondence to Sinéad Culleton, MB, BCh, BAO, FRCR, FFR (RCR), University of Utah, Department of Radiology, 30 North 1900 East, 1A071, Salt Lake City, UT 84132-2140; e-mail: Sinead.culleton@gmail.com

 Indicates open access to non-subscribers at www.ajnr.org

 Indicates article with online supplemental data.

<http://dx.doi.org/10.3174/ajnr.A7701>

proposed in the early 1950s.^{1,2} Subsequently, carotid atherosclerosis was identified as a risk factor for dementia,³ and revascularization was linked to improved cognition.^{4–6} Consequently, impaired hemodynamics secondary to flow-limiting stenosis was proposed as the primary mechanism for the association between carotid atherosclerosis and cognitive impairment.² This hypothesis was supported by an association between cerebral hypoperfusion, accelerated cognitive decline, and an increased risk of dementia.⁷

Contrary to this, however, computational models suggested that very high-grade carotid stenosis (up to 86%) was required to reduce the cerebral perfusion pressure.⁸ In addition, the Framingham Study showed that lesser degrees of stenosis down to 50% were still associated with poor executive function.⁹ Furthermore, a study of asymptomatic severe carotid stenosis

found that downstream perfusion was predominantly unaltered.¹⁰ Together, these findings suggest that an alternative etiology underpins the association between carotid atherosclerosis and cognitive decline.

Vulnerable plaque is a manifestation of advanced carotid atherosclerosis, which may play a role in cognitive decline independent of stenosis. A major determinant of vulnerable plaque is intraplaque hemorrhage (IPH), which confers an increased risk of thromboembolic stroke.^{11–13} IPH was identified as a predictor of carotid-source stroke independent of stenosis.¹⁴ Vulnerable plaque with IPH may lead to increased cerebral microemboli, which are associated with a hastened progression of dementia.¹⁵ IPH is not only a marker of thromboembolic activity,¹⁶ but it may also influence downstream cerebral hemodynamics.^{17,18} Removal of vulnerable plaque has the potential to stabilize cognitive decline.¹⁹

Carotid atherosclerosis-associated cognitive decline could be multifactorial. Plaque composition may contribute in addition to the severity of the stenosis or downstream hypoperfusion. Prior to this study, the effect of IPH status on cognitive improvement after carotid surgery was unknown. This study aimed to assess the association between IPH(+) or (–) plaque and cognition following carotid revascularization. This study hypothesized that IPH status would play a role in cognitive benefit seen after carotid intervention and that removal of IPH(+) plaque would confer the greatest benefit.

MATERIALS AND METHODS

Study Design and Population

Local institutional review board (University of Utah) approval was granted for this prospective study, and informed consent was obtained. Study procedures including data acquisition and storage were compliant with the Health Insurance Portability and Accountability Act. The study protocol (ID 17SDG33460420/NCT03068442) can be viewed at <https://clinicaltrials.gov>.

Subjects were prospectively recruited from the neurovascular consultation and outpatient services at 2 institutions (University of Utah Medical Center and VA Salt Lake City Health Care System) between January 2017 and February 2020. Consecutive subjects with carotid disease necessitating intervention, either symptomatic with ≥ 1 carotid plaque with $\geq 50\%$ stenosis or asymptomatic with $\geq 70\%$ stenosis as per the Society for Vascular Surgery guidelines²⁰ were included. The exclusion criteria were the following: 1) contraindication to CTA or MR imaging (unsuitable pacemaker, contrast allergy, ocular foreign body, estimated glomerular filtration rate of < 30 mL/min), 2) stage IV malignancy, and 3) known dementia (vascular dementia or any other cause, including Alzheimer disease). Additionally, subjects with known cardioembolic stroke factors (eg, mechanical valve, atrial fibrillation) were excluded to eliminate any confounding effects from these stroke etiologies. Finally, subjects with carotid occlusion were excluded because chronicity is often indeterminate and preocclusion lumen features could not be assessed. Before enrollment, all participants underwent a standard-of-care preintervention carotid CTA. After recruitment, subjects underwent a research carotid MR imaging and cognitive testing pre- and postintervention.

Clinical Characteristics

Relevant demographic and clinical characteristics were recorded following chart review. Cerebrovascular risk factors included age, sex, body mass index (BMI), smoking status, diabetes, renal insufficiency, hypertension, and hyperlipidemia. Diagnoses were assigned using standard clinical definitions. Renal insufficiency was an estimated glomerular filtration rate of < 45 mL/min. Hypertension was diagnosed if the average of ≥ 2 diastolic blood pressure measurements on at least 2 subsequent visits was ≥ 90 mm Hg or the average of multiple systolic blood pressure readings on ≥ 2 subsequent visits was ≥ 140 mm Hg. Hyperlipidemia was assigned when low-density lipoprotein was > 100 mg/dL. Male or female sex was self-reported. Cerebrovascular medications including antiplatelets, anticoagulants, statins, and antihypertensives were recorded.

Imaging and Postprocessing Protocols

Carotid MR Imaging. Carotid MR imaging studies were performed with a 3T magnet (Magnetom Prisma; Siemens) using the vendor's head and neck coil in conjunction with a dedicated 7-channel custom neck coil.²¹ The protocol included a TOF (axial acquisition: TR/TE = 20/3.4 ms, FOV = 240×240 mm², matrix = $320 \times 320 \times 100$, voxel = $0.77 \times 0.77 \times 0.77$ mm³); a 3D T1-weighted MPRAGE obtained 20 mm below to 20 mm above the carotid bifurcation, 1.0-mm section thickness (coronal acquisition: TR/TE/TI = 6.39/2.37/370 ms, flip angle = 15°, FOV = $180 \times 180 \times 92$ mm³, matrix = $320 \times 320 \times 120$, voxel = $0.77 \times 0.77 \times 0.77$ mm³); and a 3D T1 sampling perfection with application-optimized contrasts using different flip angle evolution (SPACE; Siemens) sequence (coronal acquisition: TR/TE = 800/22 ms, delay alternating with nutation for tailored excitation [DANTE] preparation = 150 ms, FOV = $180 \times 180 \times 77$, matrix = $320 \times 320 \times 100$, voxel = $0.77 \times 0.77 \times 0.77$).

DSC Brain Imaging. DSC was performed with an axial acquisition (TR/TE = 2070/52 ms, voxel = $2.0 \times 2.0 \times 2.0$ mm³, 5.0-mm section thickness, 100 time points/15 sections and with 1 mmol/mL^{–1} of Gadubutrol [Gadavist; Bayer Schering Pharma]). DSC was preceded by an initial contrast pre-dose to minimize errors in CBV estimates. Data were transferred to an external workstation and processed by a neuroradiologist blinded to additional imaging and clinical information using FDA-approved software (Olea Sphere, Version 3.0-SP5; Olea Medical) and automated arterial input function selection.

Imaging Analysis

Perfusion Analysis. For each cerebral hemisphere, ROIs were outlined for the anterior cerebral artery (ACA), MCA, and posterior cerebral artery (PCA) territories using arterial territory maps for reference.²² ROI analysis was conducted at 3 different levels of the brain separated by 2 axial slices, and the average measurement of these was used. Relative CBF, CBV, and MTT were assessed for the ACA, MCA and PCA territories for the ipsilateral (side of intervention) and contralateral vascular territories. Total CBF, CBV, and MTT perfusion was the sum of all the territories (ACA, MCA, and PCA) for the ipsilateral and contralateral hemispheres. Ratios were computed for the ACA, MCA, and PCA CBF, CBV, and MTT as a ratio of ipsilateral-to-contralateral territories.




FIGURE Carotid IPH in a 77-year-old male participant. An axial MPRAGE (A) shows IPH(+) eccentric plaque at the left carotid bulb (arrow). The avid hyperintense signal on this heavily T1-weighted sequence is due to methemoglobin in the blood products. Axial CTA (B) shows the corresponding CTA appearance of this plaque. The predominantly noncalcified plaque (arrow) narrowed the vessel lumen by 62%.

Finally, the Total ratios were the total sum of all 3 hemispheric vascular territories expressed as a ratio of ipsilateral-to-contralateral hemispheres.

Carotid Plaque Features. A neuroradiologist blinded to all details evaluated each MPRAGE sequence for IPH. An IPH(+) status was assigned using a ≥ 2 -fold signal threshold over the adjacent sternocleidomastoid muscle, shown to have high interrater reliability and histologic correlation as previously described (Figure).²³ Lumen measurements were the consensus of a blinded neuroradiologist and a senior neuroradiology fellow. ICA stenosis was quantified on the preintervention CTA using the NASCET criteria $[(a - b)/a] \times 100\%$, where a is the ICA diameter distal to the stenosis and b is the diameter at the level of maximal stenosis.²⁴ Maximum plaque thickness was measured on precontrast 3D T1 SPACE perpendicular to the axis of the lumen.

Ischemic Stroke Evaluation

Ischemic stroke was defined according to the American Heart Association definition of CNS infarction as brain or retinal cell death attributable to ischemia based on imaging evidence of cerebral or retinal ischemia in the carotid distribution or clinical symptoms persisting for ≥ 24 hours, with other etiologies excluded.²⁵ Preceding intervention, ischemic stroke status was determined by neurologic examination supplemented with brain DWI concurrently performed during each research carotid MR imaging. DWI was reviewed by a blinded neuroradiologist for recent infarcts. DWI trace (hyperintense) and ADC (hypointense) were the imaging determinants of recent infarction.^{26,27}

WM Disease Rating

WM disease was assessed on T2-weighted FLAIR sequences from MR imaging brain studies using the Age-Related White Matter Changes rating scale.²⁸ Ratings were performed independently by a neuroradiologist blinded to cognitive and plaque results. WM changes were defined as hyperintense lesions of ≥ 5 mm on T2 or FLAIR, and lacunes were well-defined areas of > 2 mm.²⁸ The basal ganglia, and frontal, parieto-occipital, and temporal WM were rated on a 4-point scale and presented as a total score.²⁸

Repeatable Battery for the Assessment of Neuropsychological Status Cognitive Testing

The repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a brief cognitive battery of 12 subtests, yielding 5 index scores: immediate memory index (list learning, story memory), visuospatial/constructional index (figure copy, line

orientation), language index (picture naming, semantic fluency), attention index (digit span, coding), delayed memory index (list recall, list recognition, story recall, figure recall), and a Total Scale score (all subtests).²⁹

Subtests were administered and scored according to the RBANS test manual, except for figure copy and figure recall subtests, which were scored with a modified set of scoring criteria.^{30, 31}

Data are presented as raw scores for the subtests, and the index and Total Scale scores are age-corrected standard scores (mean = 100 [SD, 15]) based on normative data in the test manual. Two additional indexes, visual and verbal indexes, were generated.³² Subtest scores were converted to age- and education-corrected scaled scores (mean = 10 [SD, 3]) using Table 2 from Duff et al.³² These age- and education-corrected scaled scores were used to generate the verbal index (list learning, story memory, list recall, list recognition, story recall) and visual index (figure copy, line orientation, coding, and figure recall).³⁰

RBANS has been previously described for subjects undergoing carotid endarterectomy^{33,34} and was administered preintervention and at least 1-month postintervention. The effects of hospitalization, anesthesia, and surgery should have been resolved by approximately 30 days postoperatively.³⁵ A research assistant administered alternate RBANS forms at visits to reduce practice effects. Across all scores (eg, raw, scaled, standard scores), higher scores indicate better cognitive performance. Baseline cognitive impairment was defined as a RBANS-1 score of ≤ 80 (> 1.3 SDs below the mean). RBANS interpretation was overseen by a neuropsychologist blinded to all patient information.

Reliable Change Assessment. Within neuropsychology, reliable change methods attempt to determine clinically meaningful cognitive change. These neuropsychology methods try to distinguish whether changes across 2 RBANS test sessions are the result of normal variations in the patient's performance and testing methods or are indeed consequential cognitive changes.³⁶ Factors that can affect cognitive testing results such as differential practice effects, systematic biases, and measurement error are taken into account.³⁶ Using regression-based prediction algorithms, predicted scores can be made for each patient's RBANS indexes and subtest scores.³⁶ Predicted postrevascularization scores, RBANS-2_{PD}, were generated with the prediction algorithms (derived from a sample of 129 cognitively intact older adults, mean age = 75.6 [SD, 7.5] years).³⁶ These scores (RBANS-2_{PD}) represent the expected RBANS scores at follow-up for each patient. Predicted RBANS-2_{PD} scores were subsequently compared with the actual observed scores of the study, RBANS-2_{OB}, by subtracting the predicted from the observed scores (RBANS-2_{OB} minus RBANS-2_{PD}).

Statistical Analysis

Continuous variables were expressed as mean (SD), and categorical variables, as frequencies. Two-sided t tests and χ^2 tests or Fisher exact tests were used to compare IPH groups. Univariable linear regression tested the association between the outcome variable

Table 1: Clinical characteristics^a

Parameter	Group (n = 23)	IPH(+) (n = 11)	IPH(−) (n = 12)	P
Participant characteristics				
Male	21 (91.3)	11 (100.0)	10 (83.3)	.48
Age (yr)	66.2 (SD, 8.0)	71.2 (SD, 7.6)	61.5 (SD, 5.2)	.002
BMI (kg/m ²)	31.7 (SD, 7.3)	33.4 (SD, 7.0)	30.1 (SD, 7.5)	.30
Right-handed	20 (87.0)	9 (81.8)	11 (91.7)	.59
Comorbidities				
Hyperlipidemia	18 (78.3)	10 (90.9)	8 (66.7)	.32
Hypertension	14 (60.9)	6 (54.6)	8 (66.7)	.68
Current smoker	4 (17.4)	0 (0.0)	4 (33.3)	.09
Prior smoker	14 (60.9)	8 (72.7)	6 (50.0)	.40
Renal insufficiency	1 (4.4)	1 (9.1)	0 (0.0)	.48
Diabetes	11 (47.8)	6 (54.6)	5 (41.7)	.54
Ischemic stroke and WM disease				
Ischemic stroke	7 (30.4)	3 (27.3)	4 (33.3)	1.00
Postintervention stroke	0 (0.0)	0 (0.0)	0 (0.0)	—
WM disease rating ^b	1.6 (SD, 1.2)	1.9 (SD, 1.4)	1.4 (SD, 1.0)	.36
Medications				
Statin	19 (82.6)	9 (81.8)	10 (83.3)	1.00
Antihypertensive	13 (56.5)	6 (54.6)	7 (58.3)	1.00
Antiplatelet	15 (65.2)	7 (63.6)	8 (66.7)	1.00
Anticoagulation	3 (13.4)	3 (27.3)	0 (0.0)	.09

Note: — indicates not assessed.

^a Data are mean (SD) or No (%).

^b Assessed for 19/23.

Table 2: Plaque, perfusion, and RBANS test characteristics^a

Parameter	Group (n = 23)	IPH(+) (n = 11)	IPH(−) (n = 12)	P
Ipsilateral plaque				
IPH	11 (47.8)	11 (100.0)	0 (0.0)	—
Ulceration	12 (52.2)	8 (72.7)	4 (33.3)	.06
Max plaque thickness (mm)	5.4 (SD, 1.6)	6 (SD, 1.9)	4.8 (SD, 1.1)	.08
NASCET (%)	68.0 (SD, 18.9)	65.1 (SD, 23.8)	70.7 (SD, 13.5)	.49
Intraluminal thrombus	3 (13.0)	1 (9.1)	2 (16.7)	1.00
Contralateral plaque				
Contra-IPH	6 (26.1)	3 (27.3)	3 (25.0)	1.00
Contra-ulceration	12 (52.2)	6 (54.6)	6 (50.0)	.83
Contra-max plaque thickness (mm)	4.2 (SD, 1.7)	4.4 (SD, 1.9)	4.1 (SD, 1.4)	.69
Contra-NASCET (%)	34.3 (SD, 30.3)	32.7 (SD, 31.4)	35.2 (SD, 31.4)	.85
Contra-intraluminal thrombus	0 (0.0)	0 (0.0)	0 (0.0)	—
Carotid intervention				
Carotid endarterectomy	20 (87.0)	10 (90.9)	10 (83.3)	.59
Right-sided intervention	14 (60.9)	7 (63.6)	4 (36.4)	1.00
Duration (min) ^b	133.1 (SD, 33.6)	132.2 (SD, 33.3)	134.1 (SD, 36.0)	.90
Perfusion				
Total CBF	34.2 (SD, 7.7)	31.5 (SD, 8.5)	36.7 (SD, 6.4)	.11
Total CBV	4.8 (SD, 0.9)	4.9 (SD, 1.1)	4.8 (SD, 0.8)	.92
Total MTT	8.3 (SD, 1.7)	9.0 (SD, 2.0)	7.6 (SD, 1.2)	.049
RBANS				
Education (yr)	15.2 (SD, 2.7)	14.8 (SD, 2.0)	15.5 (SD, 3.2)	.55
RBANS-1, ≤ 80 baseline	6 (26.1)	1 (9.1)	5 (41.7)	.16
RBANS-1, preintervention (days)	28.5 (SD, 23.5)	33 (SD, 18.8)	24.3 (SD, 27.2)	.39
Intervention to RBANS-2 (days)	212.0 (SD, 255.3)	223.1 (SD, 249.5)	201.9 (SD, 250.0)	.84
RBANS-1 time to RBANS-2 (days)	266.6 (SD, 258.1)	243.9 (SD, 259.4)	287.3 (SD, 266.7)	.70

Note: — indicates not assessed; max, maximum.

^a Data are mean (SD) or No (%).

^b Assessed for 20/23.

(RBANS scores) and each covariate. Potential confounding variables were those covariates with $P < .20$ in univariable regression, and these were subsequently assessed using multivariable linear regression. For each multivariable linear regression model, the outcome of interest was Δ RBANS (RBANS-2 minus RBANS-1), and IPH was the primary predictor variable. Each covariate was eliminated using backwards elimination until all remaining variables met a $P < .10$ threshold. Consideration was given to the number of covariates to avoid overfitting the models. Analyses were performed using STATA software (Version 17.1; StataCorp).

RESULTS

Participant, Plaque, and Perfusion Characteristics

Whole Group. Twenty-three participants (mean age, 66.2 [SD, 8.0] years; 21 men [91.3%]) were recruited and included in the analyses. The mean percentage diameter stenosis on the side of the intervention was 68.0% (SD, 18.9%). Most participants, 16 (69.6%), were asymptomatic preceding the intervention. Eleven (47.8%) were IPH(+). The right ICA was the predominant carotid artery intervened on for 14 (60.9%) participants. All subjects were initially planned for endarterectomy, and the final decision on the method of intervention was endarterectomy in 20 (87%) and angioplasty/stent placement in 3 (13%). Procedures were performed by senior vascular surgeons with a mean of 20.3 (SD, 33.6) years of experience and lasted, on average, a mean of 133.1 (SD, 3.6) minutes. RBANS-1 test scores showed that 6 (26.1%) participants were cognitively impaired at baseline. Clinical characteristics are summarized in Table 1, and carotid plaque, perfusion, and cognition are shown in Table 2.

IPH(+) and IPH(−) Groups. Two parameters were significantly different between the IPH(+) and (−) groups: age and MTT Total. Participants with IPH(+) were older at a mean age of 71.2 (SD, 7.6) years compared with 61.5 (SD, 5.2) years ($P = .002$). The MTT Total

Table 3: Mean baseline and postintervention RBANS scores

RBANS	RBANS-1	RBANS-2	Δ RBANS	P
Total Scale score	92.1 (SD, 15.5)	96.1 (SD, 15.8)	4.0 (SD, 8.7)	.04
Attention index	91.9 (SD, 15.5)	91.3 (SD, 16.4)	−0.6 (SD, 11.4)	.82
Digit span	10.3 (SD, 2.4)	9.8 (SD, 2.9)	−0.5 (SD, 2.3)	.37
Coding	34.4 (SD, 8.4)	36.3 (SD, 9.1)	2.1 (SD, 6.0)	.13
Immediate memory index	89.4 (SD, 18.2)	97.7 (SD, 14.9)	8.3 (SD, 9.4)	<.001
List learning	22.8 (SD, 5.3)	26.3 (SD, 5.4)	3.5 (SD, 3.6)	<.001
Story memory	15.8 (SD, 4.5)	14.0 (SD, 3.1)	1.3 (SD, 3.3)	.08
Delayed memory index	96.2 (SD, 16.6)	99.6 (SD, 16.3)	3.4 (SD, 11.2)	.16
List recall	4.6 (SD, 2.5)	5.5 (SD, 2.7)	0.90 (SD, 2.5)	.08
List recognition	19.1 (SD, 1.4)	18.9 (SD, 2.2)	−0.2 (SD, 1.4)	.56
Story recall	7.8 (SD, 2.9)	9.0 (SD, 2.3)	1.2 (SD, 2.6)	.048
Figure recall	12.0 (SD, 4.5)	12.9 (SD, 4.4)	0.9 (SD, 3.5)	.23
Visuospatial/constructional index	97.5 (SD, 18.0)	96.9 (SD, 18.8)	−0.6 (SD, 15.4)	.85
Figure copy	17.0 (SD, 2.8)	16.9 (SD, 2.2)	−0.1 (SD, 2.6)	.81
Line orientation	16.9 (SD, 3.4)	16.5 (SD, 3.4)	−0.4 (SD, 2.4)	.44
Language index	95.9 (SD, 10.1)	97.7 (SD, 9.8)	1.9 (SD, 8.0)	.27
Picture naming	10.0 (SD, 0.0)	9.9 (SD, 0.3)	−0.1 (SD, 0.3)	.16
Semantic fluency	17.5 (SD, 4.9)	18.6 (SD, 4.7)	1.1 (SD, 4.4)	.25
Verbal index ^a	96.1 (SD, 14.1)	103.0 (SD, 12.0)	6.9 (SD, 9.2)	.002
Visual index ^b	93.5 (SD, 17.0)	95.6 (SD, 14.7)	2.1 (SD, 11.9)	.42

Note:— Δ RBANS indicates RBANS-2 minus RBANS-1 scores.

^a Verbal index subtests are list learning, story memory, list recall, list recognition, and story recall.

^b Visual index subtests are figure copy, line orientation, coding, and figure recall.

was significantly more delayed in the presence of IPH (mean = 9.0 [SD, 2.0] versus 7.6 [SD, 1.2], $P = .049$). WM disease ratings, ischemic stroke evaluation, and baseline cognition were not statistically significant between the 2 groups. Additionally, all remaining clinical, plaque, perfusion, procedural, and cognitive parameters (Tables 1 and 2) were not significantly different between the IPH groups at baseline.

Baseline and Postintervention Cognitive Assessment

Whole-Group Analysis. RBANS domains were compared before (RBANS-1) and after (RBANS-2) the carotid intervention (Table 3). RBANS-1 was performed preintervention at a mean of 28.5 (SD, 23.5) days (range, 1–90 days) and postintervention RBANS-2 at 266.6 (SD, 258.1) days (range, 53–838 days). Whole-group analysis revealed a statistically significant improvement from baseline in 3 domains: mean Total Scale score (RBANS-1, 92.1 [SD, 15.5] versus RBANS-2, 96.1 [SD, 15.8], $P = .04$); immediate memory index (RBANS-1, 89.4 [SD, 18.2] versus RBANS-2, 97.7 [SD, 14.9], $P < .001$), and verbal index (RBANS-1, 96.1 [SD, 14.1] versus RBANS-2, 103.0 [SD, 12.0], $P = .002$). The remaining indexes were not significantly changed after the intervention.

IPH Status and Postintervention Cognition

Analysis by IPH Status. RBANS-1 and RBANS-2 mean scores were compared between IPH(+) ($n = 11$) and IPH(−) ($n = 12$) groups (Online Supplemental Data). The range during which the RBANS-2 testing occurred was not significantly different between the IPH(+) and (−) groups. The IPH(+) group had no significant improvement in postintervention scores. One index, the attention index, significantly decreased from baseline (RBANS-1, 99.4 [SD, 18.0] versus RBANS-2, 93.5 [SD, 19.4], $P = .045$). Postintervention, the IPH(−) group significantly improved in 4 scores: Total Scale score (RBANS-1, 86.4 [SD, 11.8] versus RBANS-2, 95.5 [SD, 12.4], $P = .004$), immediate memory index (RBANS-1, 82.3 [SD, 14.6] versus RBANS-2, 96.2 [SD, 14.1], $P =$

.002), delayed memory index (RBANS-1, 94.3 [SD, 14.9] versus RBANS-2, 102.4 [SD, 8.0], $P = .03$), and verbal index (RBANS-1, 94.3 [SD, 13.2] versus RBANS-2, 101.5 [SD, 107.4], $P = .009$). Subtracted mean scores (RBANS-2 minus RBANS-1) for each domain were designated Δ RBANS. IPH(+) and (−) groups had statistically significant differences in the Δ RBANS Total Scale score: IPH(+), −0.4 (SD, 6.8) versus IPH(−), 8.0 (SD, 8.5), $P = .02$; attention index, IPH(+), −5.9 (SD, 8.5) versus IPH(−), 4.3 (SD, 11.9), $P = .03$; and immediate memory index IPH(+), 4.2 (SD, 6.7) versus IPH(−), 12.2 (SD, 10.2), $P = .04$.

Multivariable Analysis of Postintervention Cognitive Outcomes

Multivariable regression models were fitted to the 3 cognitive outcomes with significantly different Δ RBANS scores between subjects with IPH(+) and (−): Δ RBANS Total Scale score, attention index, and immediate memory index. The Δ RBANS Total Scale score final model consisted of IPH(+) plaque ($\beta = -6.17$; 95% CI, −12.49–0.15; $P = .06$) and hyperlipidemia ($\beta = -9.05$; 95% CI, −16.70 to −1.40; $P = .02$). The Δ RBANS attention index final model included only IPH(+) plaque ($\beta = -10.24$; 95% CI, −19.29 to −1.20; $P = .03$). The final model for Δ RBANS immediate memory index included IPH(+) plaque ($\beta = -8.17$; 95% CI, −15.10 to −1.24; $P = .02$), BMI ($\beta = 0.49$; 95% CI, 0.02–0.97; $P = .04$), and the MTT Total ratio ($\beta = -48.51$; 95% CI, −100.70–3.69; $P = .07$). All univariable and multivariable regression analyses are shown in Online Supplemental Data.

Reliable Change Assessment

Predicted RBANS-2 scores (RBANS-2_{PD}) were generated (Online Supplemental Data). Observed RBANS-2 scores (RBANS-2_{OB}) were subtracted from the predicted (RBANS-2_{PD}) for the whole group, Group_{OB-PD}, and according to IPH status, IPH(+)_{OB-PD} and IPH(−)_{OB-PD}. For the group, the attention index group_{OB-PD} (mean, −6.3 [SD, 11.2], $P = .01$), immediate memory index

group_{OB-PD} (mean, -5.0 [SD, 8.1], $P = .007$), and language index group_{OB-PD} (mean, -3.7 [SD, 6.7], $P = .02$) significantly deviated from predicted scores. IPH(+) status showed a significantly lower-than-expected attention index IPH(+)_{OB-PD} (mean, -8.9 [SD, 10.5], $P = .02$) and immediate memory index IPH(+)_{OB-PD} (mean, -5.3 [SD, 6.8], $P = .026$). The IPH(−) group's language index significantly deviated from predicted, IPH(−)_{OB-PD} (mean, -5.2 [SD, 6.1], $P = .01$).

DISCUSSION

This study examined the changes in cognition after carotid plaque removal and the impact of IPH status on postintervention scores. The effects of stenosis, perfusion, and additional potential confounders were also evaluated. Whole-group analysis showed improvement in three domains: the overall Total Scale score, immediate memory index, and verbal index following intervention. Subgroup evaluation indicated that preintervention IPH status impacted postintervention cognition. An IPH(−) status conferred the most cognitive benefit with a significantly improved Total Scale score, immediate memory index, delayed memory index, and verbal index. For IPH(+) participants, there was no statistically significant improvement in any of the scores, and the attention index declined.

The whole group's improved cognitive performance is in keeping with prior studies that also showed an association between carotid revascularization and improved cognition.^{2,33,34,37} Takaiwa et al^{33,34} demonstrated an improved RBANS Total Scale score and immediate memory index 3 months postcarotid endarterectomy, which was sustained after 1 year. Takaiwa et al additionally reported an improved attention index.^{33,34} In the present study, attention index performance differed according to IPH status. The IPH(−) group's attention index increased, though not significantly. Conversely, the IPH(+) group's score significantly decreased. This finding suggests that IPH could differentially affect some cognitive domains more than others.

The present study evaluated 2 additional indexes that may help to lateralize pathology. The verbal and visual indexes should be most representative of the left and right cerebral hemispheric function, respectively.^{32,38} Revascularization was most beneficial for the verbal index, which increased for the whole group, again attributable to those with IPH(−) plaque; however, the visual index remained unchanged. Improved verbal scores would be expected more with a left-sided intervention.^{32,38,39} In the current study, however, this finding was not explained by the side of revascularization. One possibility is that carotid disease may affect functional brain connectivity beyond the ipsilateral vascular territory.⁴⁰

Prior studies that examined postintervention cognitive effects had not considered plaque composition.^{2,33,34,37} At the outset, this study hypothesized that intervention on IPH(+) plaque should have the greatest cognitive benefit, given its underlying thromboembolic activity,¹⁶ risk of stroke, and TIA.^{11–13} Instead, the converse occurred, and intervention on IPH(−) plaque ameliorated 4 cognitive outcomes (Total Scale score, attention index, immediate index, and verbal index). One explanation for the less-than-expected IPH(+) group's performance is microembolization during the intervention.⁴¹ An association between vulnerable plaque and postintervention ischemic events has been previously shown.^{42–45}

During carotid endarterectomy, IPH increased the embolization risk, specifically during the dissection phase.⁴³ After stent placement, a higher risk of ipsilateral ischemic events was found and correlated with IPH volume.^{44,45} In the current study, no participant had a clinically evident postprocedural ischemic stroke; however, periprocedural monitoring for silent emboli or postprocedural MR imaging for covert infarction was not performed. Cognitive improvement with IPH(−) plaque could be attributable to plaque composition. Ulceration and intraluminal thrombus, both features of plaque instability, were not statistically different between the IPH groups. However, other plaque constituents or morphologic features including calcification or a lipid-rich necrotic core may be implicated in the amelioration of some IPH(−) cognitive domains.

Confounding was addressed during statistical analysis. Three confounders were identified; 2 (hyperlipidemia and MTT Total ratio) adversely affected cognition, while 1 (BMI) had a positive association. Of the cardiovascular risk factors, only hyperlipidemia was negatively associated with the Total Scale score. High cholesterol is a known risk factor for cognitive impairment.^{46,47} Secondly, the MTT Total ratio negatively impacted the immediate memory index and was statistically longer for the IPH(+) participants. MTT measures the average time of red blood cells in the capillary circulation and can indicate impaired perfusion. In addition to steno-occlusive disease, perfusion could be influenced by plaque components including IPH volume.¹⁷ BMI was positively associated with the attention index. At an older age, a high BMI could have a protective effect against the progression of dementia.^{48–50} A survivorship bias effect is one plausible explanation for this obesity-dementia paradox.⁵¹

In a further attempt to gauge the benefit of IPH removal, the reliable change methodology was used. Baseline scores were used to estimate expected follow-up cognition on the basis of predictions derived for healthy age- and education-matched community dwellers.³⁶ This was performed to indicate whether a change in a score was statistically different from what was expected at follow-up. At baseline, participants' scores were predominantly in the RBANS average range, with a small number cognitively impaired; however, the number with cognitive impairment was not statistically different between the groups. After the intervention, the IPH(+) group had a lower-than-predicted attention index and immediate memory index. For IPH(−) participants, the language index was lower than predicted. Findings suggest that despite intervention, some cognitive abilities were unrecoverable for both groups, and the IPH(+) group was most affected. This outcome could be related to the long-standing impact on neuroplasticity from recurrent microembolization.

This study has some limitations. The sample size was small, though this limitation was comparable with that in similar studies of postintervention carotid disease and cognition.^{33,34} Despite no enrollment restrictions on demographics, the group were all white and predominantly male, which is a known population at risk of carotid disease.⁵² Accordingly, ethnicity and sex influences were unattainable. The effect of periprocedural microembolization was not examined, and routine postprocedural MR imaging screening was not conducted. Emboli monitoring or postintervention MR imaging could further address the hypotheses of an

embolic-driven mechanism of cognitive impairment. Baseline cognition was not compared with a randomized control group; however, the predicted score calculations enabled comparison with a group of community-dwelling older adults.³⁶

CONCLUSIONS

Despite these limitations, this study was a critical initial step toward elucidating the effect of carotid IPH on cognition after revascularization. While the management of carotid bifurcation stenosis has been extensively investigated with recommendations for management,²⁰ guidelines regarding the role of cognition in decision-making or stratifying patients have yet to be established. Additionally, an extended follow-up period would evaluate the long-term stability of postintervention cognition changes. Future studies are warranted to further understand the association between plaque composition and cognition.

Disclosure forms provided by the authors are available with the full text and PDF of this article at www.ajnr.org.

REFERENCES

1. Fisher M. **Senile dementia: a new explanation of its causation.** *Can Med Assoc J* 1951;65:1–7 [Medline](#)
2. Lal BK, Dux MC, Sikdar S, et al. **Asymptomatic carotid stenosis is associated with cognitive impairment.** *J Vasc Surg* 2017;66:1083–92 [CrossRef Medline](#)
3. van Oijen M, de Jong FJ, Witteman JC, et al. **Atherosclerosis and risk for dementia.** *Ann Neurol* 2007;61:403–10 [CrossRef Medline](#)
4. Turowicz A, Czapiga A, Malinowski M, et al. **Carotid revascularization improves cognition in patients with asymptomatic carotid artery stenosis and cognitive decline. Greater improvement in younger patients with more disordered neuropsychological performance.** *J Stroke Cerebrovasc Dis* 2021;30:105608 [CrossRef Medline](#)
5. Ortega G, Alvarez B, Quintana M, et al. **Asymptomatic carotid stenosis and cognitive improvement using transcervical stenting with protective flow reversal technique.** *Eur J Vasc Endovasc Surg* 2014;47:585–92 [CrossRef Medline](#)
6. Germano da Paz O, Guillaumon AT, Lopes TM, et al. **Carotid stenting versus endarterectomy cognitive outcomes.** *Ann Vasc Surg* 2014;28:893–900 [CrossRef Medline](#)
7. Wolters FJ, Zonneveld HI, Hofman A, et al; Heart-Brain Connection Collaborative Research Group. **Cerebral perfusion and the risk of dementia.** *Circulation* 2017;136:719–28 [CrossRef Medline](#)
8. Long Q, Luppi L, König CS, et al. **Study of the collateral capacity of the circle of Willis of patients with severe carotid artery stenosis by 3D computational modeling.** *J Biomech* 2008;41:2735–42 [CrossRef Medline](#)
9. Romero JR, Beiser A, Seshadri S, et al. **Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study.** *Stroke* 2009;40:1590–96 [CrossRef Medline](#)
10. Fürst H, Hartl WH, Janssen I. **Patterns of cerebrovascular reactivity in patients with unilateral asymptomatic carotid artery stenosis.** *Stroke* 1994;25:1193–1200 [CrossRef Medline](#)
11. Gupta A, Baradaran H, Schweitzer AD, et al. **Carotid plaque MRI and stroke risk: a systematic review and meta-analysis.** *Stroke* 2013;44:3071–77 [CrossRef Medline](#)
12. Schindler A, Schinner R, Altaf N, et al. **Prediction of stroke risk by detection of hemorrhage in carotid plaques: meta-analysis of individual patient data.** *JACC Cardiovasc Imaging* 2020;13:395–406 [CrossRef Medline](#)
13. Hosseini AA, Kandiyil N, Macsweeney ST, et al. **Carotid plaque hemorrhage on magnetic resonance imaging strongly predicts recurrent ischemia and stroke.** *Ann Neurol* 2013;73:774–84 [CrossRef Medline](#)
14. McNally JS, McLaughlin MS, Hinckley PJ, et al. **Intraluminal thrombus, intraplaque hemorrhage, plaque thickness, and current smoking optimally predict carotid stroke.** *Stroke* 2015;46:84–90 [CrossRef Medline](#)
15. Purandare N, Voshaar RC, Morris J, et al. **Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia.** *Biol Psychiatry* 2007;62:339–44 [CrossRef Medline](#)
16. Altaf N, Goode SD, Beech A, et al. **Plaque hemorrhage is a marker of thromboembolic activity in patients with symptomatic carotid disease.** *Radiology* 2011;258:538–45 [CrossRef Medline](#)
17. Hashimoto N, Hama S, Yamane K, et al. **Carotid arterial intraplaque hemorrhage and calcification influences cerebral hemodynamics.** *Neurosurg Rev* 2013;36:421–27 [CrossRef Medline](#)
18. Huo R, Xu H, Yang D, et al. **Associations between carotid plaque characteristics and improvement of cerebral blood perfusion in patients with moderate to severe carotid stenosis undergoing carotid endarterectomy.** *J Magn Reson Imaging* 2021;53:613–25 [CrossRef Medline](#)
19. Dempsey RJ, Jackson DC, Wilbrand SM, et al. **The preservation of cognition 1 year after carotid endarterectomy in patients with prior cognitive decline.** *Neurosurgery* 2018;82:322–28 [CrossRef Medline](#)
20. AbuRahma AF, Avgerinos ED, Chang RW, et al. **Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease.** *J Vasc Surg* 2022;75:4s–22s [CrossRef Medline](#)
21. Beck MJ, Parker DL, Bolster BD Jr, et al. **Interchangeable neck shape-specific coils for a clinically realizable anterior neck phased array system.** *Magn Reson Med* 2017;78:2460–68 [CrossRef Medline](#)
22. Kim DE, Park JH, Schellingerhout D, et al. **Mapping the supratentorial cerebral arterial territories using 1160 large artery infarcts.** *JAMA Neurol* 2019;76:72–80 [CrossRef Medline](#)
23. McNally JS, Yoon HC, Kim SE, et al. **Carotid MRI detection of intraplaque hemorrhage at 3T and 1.5T.** *J Neuroimaging* 2015;25:390–96 [CrossRef Medline](#)
24. Fox AJ. **How to measure carotid stenosis.** *Radiology* 1993;186:316–18 [CrossRef Medline](#)
25. Sacco RL, Kasner SE, Broderick JP, et al; Council on Nutrition, Physical Activity and Metabolism. **An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.** *Stroke* 2013;44:2064–89 [CrossRef Medline](#)
26. Lansberg MG, Thijs VN, O'Brien MW, et al. **Evolution of apparent diffusion coefficient, diffusion-weighted, and T2-weighted signal intensity of acute stroke.** *AJNR Am J Neuroradiol* 2001;22:637–44 [Medline](#)
27. Warach S, Gaa J, Siewert B, et al. **Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging.** *Ann Neurol* 1995;37:231–41 [CrossRef Medline](#)
28. Wahlund LO, Barkhof F, Fazekas F, et al; European Task Force on Age-Related White Matter Changes. **A new rating scale for age-related white matter changes applicable to MRI and CT.** *Stroke* 2001;32:1318–22 [CrossRef Medline](#)
29. Randolph C, Tierney MC, Mohr E, et al. **The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.** *J Clin Exp Neuropsychol* 1998;20:310–19 [CrossRef Medline](#)
30. Duff K, Patton D, Schoenberg MR, et al. **Age- and education-corrected independent normative data for the RBANS in a community dwelling elderly sample.** *Clin Neuropsychol* 2003;17:351–66 [CrossRef Medline](#)
31. Duff K, Leber WR, Patton DE, et al. **Modified scoring criteria for the RBANS figures.** *Appl Neuropsychol* 2007;14:73–83 [CrossRef Medline](#)
32. Duff K, Langbehn DR, Schoenberg MR, et al. **Normative data on and psychometric properties of Verbal and Visual Indexes of the RBANS in older adults.** *Clin Neuropsychol* 2009;23:39–50 [CrossRef Medline](#)
33. Takaiwa A, Kuwayama N, Akioka N, et al. **Effect of carotid endarterectomy on cognitive function in patients with asymptomatic carotid**

- artery stenosis. *Acta Neurochir (Wien)* 2013;155:627–33 [CrossRef Medline](#)
34. Takaiwa A, Hayashi N, Kuwayama N, et al. **Changes in cognitive function during the 1-year period following endarterectomy and stenting of patients with high-grade carotid artery stenosis.** *Acta Neurochir (Wien)* 2009;151:1593–1600 [CrossRef Medline](#)
 35. Evered L, Silbert B, Knopman DS, et al; Nomenclature Consensus Working Group. **Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018.** *Anesthesiology* 2018;129:872–79 [CrossRef Medline](#)
 36. Hammers DB, Suhrie KR, Porter SM, et al. **Generalizability of reliable change equations for the RBANS over one year in community-dwelling older adults.** *J Clin Exp Neuropsychol* 2020;42:394–405 [CrossRef Medline](#)
 37. Watanabe J, Ogata T, Higashi T, et al. **Cognitive change 1 year after CEA or CAS compared with medication.** *J Stroke Cerebrovasc Dis* 2017;26:1297–1305 [CrossRef Medline](#)
 38. Wilde MC. **The validity of the repeatable battery of neuropsychological status in acute stroke.** *Clin Neuropsychol* 2006;20:702–15 [CrossRef Medline](#)
 39. Ishihara H, Oka F, Shirao S, et al. **Cognitive outcome differences on the side of carotid artery stenting.** *J Vasc Surg* 2013;57:125–30 [CrossRef Medline](#)
 40. He S, Liu Z, Xu Z, et al. **Brain functional network in chronic asymptomatic carotid artery stenosis and occlusion: changes and compensation.** *Neural Plast* 2020;2020:9345602 [CrossRef Medline](#)
 41. Krámská L, Kovář M, Hrešková L, et al. **Neuropsychological performance after carotid endarterectomy.** *J Integr Neurosci* 2022;21:36 [CrossRef Medline](#)
 42. Verhoeven BA, de Vries JP, Pasterkamp G, et al. **Carotid atherosclerotic plaque characteristics are associated with microembolization during carotid endarterectomy and procedural outcome.** *Stroke* 2005;36:1735–40 [CrossRef Medline](#)
 43. Altaf N, Beech A, Goode SD, et al. **Carotid intraplaque hemorrhage detected by magnetic resonance imaging predicts embolization during carotid endarterectomy.** *J Vasc Surg* 2007;46:31–36 [CrossRef Medline](#)
 44. Zhao G, Tang X, Tang H, et al. **Recent intraplaque hemorrhage is associated with a higher risk of ipsilateral cerebral embolism during carotid artery stenting.** *World Neurosurg* 2020;137:e298–307 [CrossRef Medline](#)
 45. Ji A, Lv P, Dai Y, et al. **Associations between carotid intraplaque hemorrhage and new ipsilateral ischemic lesions after carotid artery stenting: a quantitative study with conventional multi-contrast MRI.** *Int J Cardiovasc Imaging* 2019;35:1047–54 [CrossRef Medline](#)
 46. van Vliet P. **Cholesterol and late-life cognitive decline.** *J Alzheimers Dis* 2012;30(Suppl 2):S147–12 [CrossRef Medline](#)
 47. Svensson T, Sawada N, Mimura M, et al. **The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up.** *Transl Psychiatry* 2019;9:26 [CrossRef Medline](#)
 48. Besser LM, Gill DP, Monsell SE, et al. **Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease.** *Alzheimer Dis Assoc Disord* 2014;28:36–43 [CrossRef Medline](#)
 49. Dahl AK, Löppönen M, Isoaho R, et al. **Overweight and obesity in old age are not associated with greater dementia risk.** *J Am Geriatr Soc* 2008;56:2261–66 [CrossRef Medline](#)
 50. Moser VA, Pike CJ. **Obesity and sex interact in the regulation of Alzheimer's disease.** *Neurosci Biobehav Rev* 2016;67:102–18 [CrossRef Medline](#)
 51. Michaud TL, Siahpush M, Farazi PA, et al. **The association between body mass index, and cognitive, functional, and behavioral declines for incident dementia.** *J Alzheimers Dis* 2018;66:1507–17 [CrossRef Medline](#)
 52. Dossabhoy S, Arya S. **Epidemiology of atherosclerotic carotid artery disease.** *Semin Vasc Surg* 2021;34:3–9 [CrossRef Medline](#)